



TO:

B.A. Dyos,

DATE: 27th February 1981

FROM:

B.J. Barber.

COPIES TO:

SUBJECT

VISIT REPORT BIRMINGHAM CHILDRENS HOSPITAL 9.2.81

Contact : Dr. F. Hill - Director.

Most of the West Midlands R.H.A. have been firm Armour accounts for about four years. Dr. Hill's attitude was therefore one of "friendly hostility"

I determined the following :-

1. Usage

Total usage 800,000 i.u. per year (this account only)
Commercial use not given probably about half. Cryo used mainly to treat V.W. disease.

18% of Haemophilia A patients have inhibitors which are mainly treated along the traditional lines recommended by Oxford.

2. Choice of Product.

Dicated by three parameters :-

- i) Price. Talked at 7.2p but R.H.A. contracted to Armour until October 1981. (he changed his mind on this - will check at R.H.A. H.Q.)
- ii) Hepatitis Risk. He stated that some commercial products have a higher rate of infectivity than others. I questioned this closely - no names were given - the inference was that Armour's product is the cleanest. Supposedly info. from U.K. directors. I have no evidence of this at all (and frankly don't believe it!)

We discussed the general concern of altered liver architecture in haemophiliacs and the possibility that some of this could be caused by the high protein levels of some Factor VIII preparation. He thought that the Armour high potency product was a step in the right direction.

- iii) Packaging. Armour make various H/T packs available for this R.H.A.

I am to contact Dr. John Stewart, Regional Scientific Officer, West Midlands R.H.A. re tender for future contracts.

Regards,

GRO-C: Barber